Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus FLOVENT DISKUS 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus FLOVENT DISKUS 100.
CORTIFOAM vs FLOVENT DISKUS 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Fluticasone propionate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and suppresses eosinophil activity.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
100 mcg inhaled orally twice daily
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
The terminal elimination half-life of fluticasone propionate is approximately 7.8 hours (range 5-11 hours) following inhalation. This supports twice-daily dosing, though the therapeutic effect is driven by local lung retention rather than systemic half-life.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Fluticasone propionate is primarily eliminated via hepatic metabolism (CYP3A4) with less than 5% of a dose excreted unchanged in urine. Fecal excretion accounts for approximately 90% of the absorbed dose (as metabolites). Biliary elimination is minimal.
Category C
Category C
Corticosteroid
Corticosteroid